GlaxoSmithKline PLC brings more certainty to its consumer health business plans, potentially including shedding lagging brands and product lines, by acquiring full control of the OTC drug and nutritional products joint venture it has operated with Novartis AG.
After announcing the £9.2bn ($13bn) acquisition of Novartis' 36.5% share of the JV on March 27, GSK executives wasted no time identifying the firm's Horlicks nutritional products line and its...